Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has completed its portfolio of wholly-owned Family 2 Patents for RECCE® Anti-Infectives with the China National Intellectual Property Administration formally granting a new Patent Family 2.
The patent 'Copolymer and Method for Treatment of Bacterial Infection' has now been granted in China with an expiry of 2035 and, as a result, Recce is now patent-protected in all major global pharmaceutical markets.
This granted Chinese patent claims relate to RECCE® 327 (R327) and RECCE® 529 (R529), most notably methods of manufacture, administration and application to treat a broad range of common human infections.
Completes portfolio
Chief executive officer James Graham said: “We thank the China National Intellectual Property Administration for their recognition of the significant potential of Recce’s new class of anti-infectives.
"We are proud to have now completed our portfolio of Family 2 Patents and now have coverage globally until at least 2035.”
Patents have now been granted in China, Australia, USA, Europe, Germany, Spain, France, UK, Italy, Sweden and Japan with all due to expire in 2035.
Massive China market
China is the second largest pharmaceutical market in the world, worth approximately US$140 billion in 2021.
The industry has grown at an average annual rate of around 3.2% in 2023, and this growth is expected to continue due to increasing demand, healthcare reforms and government support for pharmaceutical research and development (R&D).
About Recce Pharmaceuticals
Recce Pharmaceuticals is developing a new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
The company’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives:
- RECCE® 327 is an intravenous and topical therapy being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms;
- RECCE® 435 as an orally administered therapy for bacterial infections; and
- RECCE® 529 is for viral infections.
Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses – the challenge of all existing antibiotics to date.